Skip to main content
Article thumbnail
Location of Repository

Arq Bras Endocrinol Metab 2007;51/5 New Drugs in Thyroid Cancer

By Endocrinol Metab

Abstract

This review is focused on “new drugs ” that might be developed for thyroid cancer treatment. Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases. There is good evidence that these genetic lesions are causative events in thyroid cancer initiation or progression. Therefore, novel compounds able to target these kinases might be useful for thyroid cancer treatment. The power of this approach is witnessed by the examples of BCR-ABL, c-KIT and EGFR inhibitors in the treatment of chronic myelogenous leukemia (CML), gastro-intestinal stromal tumors (GIST) and non-small cell lung carcinoma (NSCLC). (Arq Bras Endocrinol Meta

Topics: CARCINOMA SUBTYPES
Year: 2009
OAI identifier: oai:CiteSeerX.psu:10.1.1.135.9142
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://citeseerx.ist.psu.edu/v... (external link)
  • http://www.scielo.br/pdf/abem/... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.